Approved accessible "entrectinib capsules"

ROZLYTREK is a kinase inhibitor indicated for the treatment of:
• Adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.
• Adult and pediatric patients 12 years of age and older with solid tumors that:
o have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation,
o are metastatic or where surgical resection is likely to result in severe morbidity, and
o have progressed following treatment or have no satisfactory alternative therapy.
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

How To access entrectinib capsules?

Rozlytrek (entrectinib capsules) for oral use Initial U.S. Approval: 2019
To access entrectinib capsules sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN's Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj)